{"nctId":"NCT02279732","briefTitle":"Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin","startDateStruct":{"date":"2014-10-13","type":"ACTUAL"},"conditions":["Lung Cancer (NSCLC)"],"count":342,"armGroups":[{"label":"Arm 1: Carboplatin + Paclitaxel + Ipilimumab","type":"EXPERIMENTAL","interventionNames":["Biological: Paclitaxel","Biological: Carboplatin","Biological: Ipilimumab"]},{"label":"Arm 2: Carboplatin + Paclitaxel + Placebo","type":"EXPERIMENTAL","interventionNames":["Biological: Paclitaxel","Biological: Carboplatin","Other: Placebo"]}],"interventions":[{"name":"Paclitaxel","otherNames":["Taxol®","BMS-181339"]},{"name":"Carboplatin","otherNames":["Paraplatin®"]},{"name":"Ipilimumab","otherNames":["MDX-010","BMS-734016"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Subjects with NSCLC of predominantly squamous histology documented by histology or cytology from brushing, washing or needle aspiration of a defined lesion but not from sputum cytology alone\n* Stage IV or Recurrent NSCLC (per the 7th International Association for the Study of Lung Cancer (IASLC) classification)\n* At least 1 measurable tumor lesion, as defined by mWHO criteria, that is not located in a previously irradiated area\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤1\n\nExclusion Criteria:\n\n* Brain metastases\n* Malignant pleural effusion that is recurrent\n* Documented history of severe autoimmune or immune mediated symptomatic disease that required prolonged (more than 2 months) systemic immunosuppressive (ie, steroids) treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS) of All Randomized Participants Who Received at Least One Dose of Blinded Study Therapy","description":"OS is defined as the time from the date of randomization until the date of death. For those participants who have not died, OS was censored on the last date the participant was known to be alive.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival of All Randomized Participants","description":"OS is defined as the time from the date of randomization until the date of death. For those participants who have not died, OS was censored on the last date the participant was known to be alive.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS) Among All Randomized Particiapants Who Received at Least One Dose of Blinded Study Therapy Using Modified World Health Organization (mWHO) Criteria","description":"PFS is defined as the time between the date of randomization and the date of progression per mWHO criteria or death, whichever occurs first. A participant who died without reported progression per mWHO criteria was considered to have progressed on the date of death. For those participants who remained alive and had not progressed, PFS was censored on the date of last evaluable tumor assessment. For those participants who remained alive and had no recorded post-baseline tumor assessment, PFS was censored on the day of randomization.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":40,"n":98},"commonTop":["Neutropenia","Leukopenia","Anaemia","Haemoglobin decreased","Thrombocytopenia"]}}}